Sunitinib for metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Sunitinib for metastatic renal cell carcinoma

Published:2010-09 Issue:9 Volume:6 Page:1377-1385
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Mukherji Deborah¹,Larkin James²,Pickering Lisa

Affiliation:

1. St Georges Hospital, Blackshaw Road, London SW17 0QT, UK

2. Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK

Abstract

Sunitinib is an orally available, multitargeted tyrosine kinase inhibitor licensed for the treatment of metastatic renal cell carcinoma. This article is an in-depth review of the mechanism of action of sunitinib, rationale for dose and schedule, toxicity and clinical efficacy. Other targeted therapies and treatment combinations for renal cell carcinoma are discussed. The use of sunitinib for other indications, biomarkers of response and future directions are explored.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon.10.94

Reference64 articles.

1. Renal-Cell Carcinoma

2. Five-year survival after surgical treatment for kidney cancer

3. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

4. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oxindole–benzothiazole hybrids as CDK2 inhibitors and anticancer agents: design, synthesis and biological evaluation;BMC Chemistry;2024-09-13

2. Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity;Archiv der Pharmazie;2024-07-23

3. Quinazoline‐oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies;Archiv der Pharmazie;2024-07-12

4. Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma;Bioorganic Chemistry;2024-05

5. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study;Future Oncology;2012-12